User:ChrisMisu/Cost of drug development

User:ChrisMisu/Cost of drug development

Article body
Pérez-Rodríguez and Valcarcel (2012) noted that R&D in the pharmaceutical industry is riskier than in other industries because it is lengthy, costly, and highly uncertain, particularly due to unpredictable human physiological responses to drugs.


 * Drug Approval and Stock Prices: The study's findings suggest that FDA approvals and other R&D-related news significantly impact pharmaceutical companies' stock prices, though not always as drastically as might be expected. This could inform an understanding of how drug price negotiations and patent dynamics affect Pfizer's financial performance.


 * R&D Impact on Financial Performance: The relationship between R&D milestones (like clinical trial outcomes or regulatory approvals) and stock price volatility highlights the financial implications of Pfizer's R&D decisions and outcomes.